share_log

We Think HealthEquity's (NASDAQ:HQY) Robust Earnings Are Conservative

We Think HealthEquity's (NASDAQ:HQY) Robust Earnings Are Conservative

我們認爲HealthEquity(納斯達克股票代碼:HQY)的強勁收益是保守的
Simply Wall St ·  2023/12/13 07:04

Even though HealthEquity, Inc.'s (NASDAQ:HQY) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are encouraging for the future of the company.

儘管 HealthEquity, Inc.s(納斯達克股票代碼:HQY)最近發佈的業績表現強勁,市場似乎沒有注意到。投資者可能錯過了一些對公司未來感到鼓舞的潛在因素。

Check out our latest analysis for HealthEquity

查看我們對HealthEquity的最新分析

earnings-and-revenue-history
NasdaqGS:HQY Earnings and Revenue History December 13th 2023
納斯達克股票代碼:HQY 收益和收入記錄 2023 年 12 月 13 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

Importantly, our data indicates that HealthEquity's profit was reduced by US$13m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If HealthEquity doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

重要的是,我們的數據表明,由於不尋常的項目,HealtheQuity的利潤在過去一年中減少了1300萬美元。儘管由於不尋常的項目而產生的扣除首先令人失望,但有一線希望。當我們分析全球絕大多數上市公司時,我們發現重要的不尋常項目通常不會重演。鑑於這些細列項目被認爲是不尋常的,這並不奇怪。如果HealthEquity看到這些不尋常的支出不會重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On HealthEquity's Profit Performance

我們對HealthEquity盈利表現的看法

Unusual items (expenses) detracted from HealthEquity's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that HealthEquity's statutory profit actually understates its earnings potential! And one can definitely find a positive in the fact that it made a profit this year, despite losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about HealthEquity as a business, it's important to be aware of any risks it's facing. At Simply Wall St, we found 1 warning sign for HealthEquity and we think they deserve your attention.

去年,不尋常的項目(支出)減損了HealtheQuity的收益,但明年我們可能會看到改善。基於這一觀察,我們認爲HealthEquity的法定利潤實際上可能低估了其盈利潛力!儘管去年虧損,但它今年還是實現了盈利,這一事實肯定會給人留下積極的印象。當然,在分析其收益時,我們才剛剛浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。如果您想進一步了解HealtheQuity作爲一家企業,請務必意識到其面臨的任何風險。在 Simply Wall St,我們發現了 1 個 HealtheQuity 的警告信號,我們認爲它們值得你關注。

This note has only looked at a single factor that sheds light on the nature of HealthEquity's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

本說明僅研究了揭示HealtheQuity利潤性質的單一因素。但是,還有很多其他方法可以告知你對公司的看法。有些人認爲高股本回報率是高質量業務的好兆頭。儘管可能需要代表你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論